688373 Shanghai Micurx Pharmaceutical
- 3.71
- -0.15-3.89%
Shanghai Micurx Pharmaceutical News
Mengke Pharmaceutical: Achieved revenue of 60.74 million yuan in the first half of 2024, a year-on-year increase of 44%.
In the first half of 2024, the revenue reached 60.7382 million yuan, a year-on-year growth of 44.24%. The R&D investment reached 166.1674 million yuan, a year-on-year growth of 72.91%; the R&D investment accounted for 273.58% of revenue, an increase of 45.37 percentage points compared to the same period last year. Shanghai, September 2, 2024 / PRNewswire / - On August 29, 2024, Shanghai Mengke Pharmaceutical Co., Ltd. ("Mengke Pharmaceuticals", 688373.SH) disclosed its semi-annual report for 2024. During the reporting period, the company achieved revenue of 60.7382 million yuan, a year-on-year growth.
Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Shanghai Mengke Pharmaceutical Co., Ltd.
Meinuo Pharmaceutical (688373.SH) released its first half financial performance, with a net loss of 0.201 billion yuan.
Mengke Pharmaceutical (688373.SH) released its semi-annual report for 2024, during which period the company achieved revenue...
Mengke Pharmaceutical (688373.SH): net loss of 201 million yuan in the first half of the year.
Gelonghui August 28th | Meike Pharma (688373.SH) released its 2024 interim report, with revenue of 60.738 million yuan, a year-on-year increase of 44.24%; net income attributable to the company's shareholders amounted to -0.201 billion yuan.
Express News | Star Market closing review: Orthopedic material concept stock, Ausin Medical, rose by the daily limit, while most semiconductor sector stocks fell.
Mengke Pharmaceutical (688373.SH): intends to continue using temporarily idle raised funds of no more than 0.5 billion yuan for cash management.
On August 6th, Gelonghui reported that Mengke Pharmaceuticals (688373.SH) intends to continue using temporarily idle raised funds not exceeding RMB 0.5 billion (including principal) for cash management, with a single maximum term not exceeding 12 months, and valid within 12 months from the date of approval by the company's board of directors. Within the above-mentioned amount and validity period, the funds can be rolled over and used.
Mengke Pharmaceuticals showcased innovative antibiotic research results at the Seventh World Bronchiectasis Conference.
At the 7th World Bronchiectasis Conference, Mengke Pharmaceutical showcased the latest research progress of its pipeline products MRX-8 and MRX-5. Three important research results further support the potential of MRX-8 and MRX-5 in the treatment of non-tuberculous mycobacterial pulmonary disease and Pseudomonas aeruginosa infection. Dundee, Scotland, July 17, 2024 / PRNewswire / - Shanghai Mengke Pharmaceutical Co., Ltd. ("Mengke Pharmaceutical", 688373.SH) held the seventh World Bronchiectasis Conference from July 4th to 6th, 2024 in Dundee, Scotland.
Mengke Pharmaceuticals (688373.SH): 13.4044 million shares of the first public offering of restricted shares will be listed and traded on July 15th.
Mengke Pharmaceutical Co., Ltd. (688373.SH) announced that the stock will be listed as initial restricted shares. The stock subscription party...
Mengke Pharmaceuticals (688373): The pioneer of innovative antibiotics leads a new chapter in the treatment of infectious diseases.
The problem of multi-drug resistant infections is serious, and there is an urgent global clinical demand. As antibiotics are widely used, drug-resistant bacteria have become a major threat to human health. According to research predictions, by 2050, the number of people worldwide who die from drug-resistant bacteria each year will reach 10.
MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China
MicuRx Pharma's Phase 1 China Trial for Polymyxin Antibiotic Shows Good Safety Profile
Mengke Pharmaceutical: The Phase I clinical trial of the independently developed antimicrobial drug MRX-8 in China has been successfully completed.
According to the data from the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening situations every year due to drug-resistant bacterial infections. MRX-8 not only performs well in safety and tolerability but also shows strong antibacterial activity against multi-drug-resistant gram-negative bacteria, with significant clinical application potential. In China, the total treatment days of antibiotics for multi-drug-resistant gram-negative bacterial infections increased from 43 million days in 2018 to 68.4 million days in 2023, with a compound annual growth rate of 10.3% during this period. [1] Shanghai, June 5, 2024 / PRNewswire / -
Express News | Mengke Pharmaceutical announced that the Phase I clinical trial of its independently developed new injection-type polymyxin antibiotic MRX-8 in China has recently been completed and achieved expected goals.
Express News | MENGKE Pharmaceuticals: the Phase I clinical trial of the new injection multi-viscous streptomycin antibacterial drug MRX-8 in China has achieved the expected goal.
Mengke Pharmaceutical: Revenue of about 33.02 million yuan in the first quarter of 2024 increased 91.10% year-on-year
SHANGHAI, April 28, 2024/PRNewswire/ -- On the evening of April 25, the company released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 33.0161,000 yuan, an increase of 91.10% over the previous year; realized net profit to mother of 102.1366 million yuan; and total R&D investment of 84.646,900 yuan, an increase of 94.73% over the previous year. Evidence-based medical research continues to advance, accelerating the release of clinical potential. The company's first commercial product, contizolamide tablets, is a new generation of oxazolidinone antimicrobials independently designed and developed by the company, which can be used to treat complex skin and soft tissues
Mengke Pharmaceutical (688373.SH) announced first-quarter results with a net loss of 102 million yuan
Mengke Pharmaceutical (688373.SH) released its report for the first quarter of 2024. The company achieved operating income of 3 during the reporting period...
Mengke Pharmaceutical (688373.SH): The ban on 2.631 million restricted shares was lifted on April 23
Gelonghui, April 12丨Mengke Pharmaceutical (688373.SH) announced that the total number of shares in circulation during the current stock listing was 2.631 million shares. The stock listing and circulation date is April 23, 2024.
Mengke Pharmaceutical (688373.SH): Shareholders, directors and executives completed a plan to increase their shareholding in the company
Gelonghui, April 12, 丨 Mengke Pharmaceutical (688373.SH) announced that as of April 11, 2024, the increase holder had accumulated 569,800 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.087% of the company's total share capital, with a total increase of 2,951,649 yuan. The implementation of this holdings increase plan has been completed. Entities of this increase include some shareholders, directors and senior management of 5% or more of the company, including: MICURX (HK) LIMITED (hereinafter referred to as “Mengke Hong Kong”), the chairman of the company
Mengke Pharmaceutical (688373.SH): Relevant shareholders increased their total shares by 0.04%
Gelonghui, April 8, 丨 Mengke Pharmaceutical (688373.SH) announced that as of April 8, 2024, the increase holder had accumulated 269,800 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.04% of the company's total share capital. The total amount of increase in holdings was 13.297.39 million yuan, which has exceeded 50% of the lower limit of 500,000 shares in this increase plan. The implementation of this holdings increase plan has not yet been completed, and the entities that have increased their holdings will continue to implement the holdings increase in accordance with the holdings increase plan. The entities of this increase in holdings include some shareholders, directors and senior management personnel of 5% or more, including: Company 5
Analysis
Price Target
No Data
No Data